The study directly tested whether H2A.Z contributes to the maintenance of H3K27me3 in plants. H2A.Z is a variant of the H2A histone protein, and H3K27me3 is a histone modification associated with transcriptional repression. Previous genome-wide studies had raised the possibility that H2A.Z contributes to H3K27me3 homeostasis in Arabidopsis, where the two features are often found together. The new research went beyond colocalization by genetically reducing H2A.Z and then measuring chromatin enrichment, protein abundance and gene expression. The siQ-ChIP analysis revealed both the twofold global decline in H2A.Z and an altered normalized distribution of H3K27me3 across the genome.

Genes carrying H3K27me3 were substantially overrepresented among those showing differential expression in the hta9 hta11 mutants, linking changes in the repressive chromatin state with altered transcriptional behavior. The pattern nevertheless varied among genomic regions rather than following a single proportional shift. The study did not characterize the locus-level reductions as a complete loss of H3K27me3, and it did not report their magnitude in the supplied evidence. Its results support the conclusion that perturbing H2A.Z enrichment and variant composition is sufficient to alter H3K27me3 distribution and abundance in a locus-specific fashion. They are also consistent with a functional relationship between these conserved chromatin features, although the experiments do not establish that H3K27me3 changes directly caused every observed difference in gene expression.

One possible contributor to the locus-specific effects was the transcriptional regulator FUS3. The researchers’ analyses raised the possibility that ectopic expression of FUS3 in hta9 hta11 seedlings contributed to altered H3K27me3 enrichment at its target genes, offering a possible route through which reduced H2A.Z could affect chromatin regulation. This remains a qualified interpretation rather than a demonstrated universal mechanism. The work was conducted in a specific Arabidopsis mutant background and combined genetic perturbation with chromatin profiling, protein-abundance measurements and gene-expression analysis. Its scope is therefore the relationship between H2A.Z and H3K27me3 in that experimental system, not evidence for equivalent effects across plant species, tissues or developmental conditions. The article was published as an early-access, peer-reviewed version in BMC Plant Biology and was identified as subject to further editorial revision.

Subject of Research: Effects of H2A.Z perturbation on H3K27me3 distribution and gene expression in Arabidopsis thaliana

Article Title: Perturbation of H2A.Z enrichment and variant composition in Arabidopsis thaliana is sufficient to alter H3K27me3 distribution and abundance in a locus-specific fashion

Article References: Long, J., Agreda, G., Sliger, S., Fawley, J. R., Pascuzzi, P. E., Dickson, B. M., Drown, B., & Ogas, J. (2026). Perturbation of H2A.Z enrichment and variant composition in Arabidopsis thaliana is sufficient to alter H3K27me3 distribution and abundance in a locus-specific fashion. BMC Plant Biology. https://doi.org/10.1186/s12870-026-09899-4

Image Credits: AI Generated

DOI: 10.1186/s12870-026-09899-4

Keywords: Arabidopsis thaliana, H2A.Z, H3K27me3, histone variants, chromatin regulation, plant epigenetics, gene expression, FUS3, siQ-ChIP, mass spectrometry, Perturbation, enrichment

A central theme of the review is that m6A deposition is not random. The authors describe how the chromatin environment, the act of transcription itself, and RNA processing steps jointly govern where the mark is placed along transcripts. This multilayered control means that m6A patterns reflect the state of the genome and the cell’s transcriptional activity, coupling epigenetic regulation directly to the fate of RNA molecules.

Once deposited, the modification is interpreted by a coordinated molecular machinery. Enzymes known as writers install m6A, erasers remove it, and reader proteins recognise the mark and translate it into functional outcomes. According to the review, these outcomes include altered chromatin function as well as changes in RNA splicing, stability, localisation within the cell and translation into protein.

The authors argue that this dynamic regulatory network enables cells to adapt to environmental changes. They illustrate how m6A orchestrates cellular stress responses, helping cells adjust gene expression when conditions shift, and how it contributes to metabolic homeostasis. The review also connects the modification to antitumour immunity, indicating that m6A regulation influences how tumour cells interact with the immune system.

Pathological consequences feature prominently in the analysis. Dysregulation of the m6A machinery has been implicated in brain disorders, including neurodegenerative diseases, and in cancer. By dissecting how writers, erasers and readers normally cooperate, the review offers a framework for understanding how their malfunction may contribute to disease processes.

Looking toward the clinic, the authors highlight translational prospects of m6A biology. These include the development of specific small-molecule inhibitors that could target the enzymes controlling the modification, and precise RNA editing technologies that could correct aberrant m6A patterns. The review also addresses the remaining challenges for clinical interventions targeting m6A, underscoring that translating mechanistic insights into therapies remains a work in progress.

As a review article, the publication does not present new experimental data but consolidates the current state of a fast-moving field. Its significance lies in framing m6A as a hub that connects chromatin regulation, RNA processing and cellular physiology, offering researchers a roadmap for studying the modification in health and disease.

Subject of Research: The RNA modification N6-methyladenosine and its roles in gene regulation, cellular responses and disease

Article Title: Molecular functions, cellular responses and pathological implications of the RNA modification N6-methyladenosine

Article References: Kang, Z., Zhang, F., Ming, G.-L., Song, H., & Liu, J. (2026). Molecular functions, cellular responses and pathological implications of the RNA modification N6-methyladenosine. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-026-01039-y

Image Credits: AI Generated

DOI: 10.1038/s41580-026-01039-y

Keywords: m6A, RNA modification, gene expression, epitranscriptomics, writers and erasers, reader proteins, cancer, neurodegenerative disease, antitumour immunity, chromatin regulation, RNA editing, small-molecule inhibitors

Researchers investigated resveratrol glucoside, abbreviated R-glc, using in-vitro models of cellular senescence. The work focused on the mitochondria–chromatin axis, the coordinated relationship between mitochondria and the regulation of chromatin structure that the study identifies as a central feature of senescence. R-glc attenuated several senescence-associated phenotypes at low concentrations. In contrast, the parent compound resveratrol showed dose-dependent cytotoxicity, a limitation that has constrained its clinical utility. The comparison indicates a more favorable cytotoxicity profile for R-glc within the laboratory systems tested; it does not establish safety in people.

At the mitochondrial level, R-glc enhanced oxidative phosphorylation and reduced the cells’ dependence on glycolysis. The researchers therefore observed changes in both components of cellular energy metabolism, rather than only a reduction in a single senescence marker. The supplied study report does not provide the exact cell models, concentrations, quantitative measurements or statistical details needed to assess the magnitude or reproducibility of these effects. Accordingly, the findings demonstrate altered mitochondrial function in vitro without showing that R-glc can reverse aging, prevent age-related disease or improve health in an organism.

R-glc also upregulated SIRT6, an NAD+-dependent deacetylase associated with epigenetic regulation, and decreased H3K9 acetylation, a modification of histone H3 at lysine 9. The investigators interpreted the combination as indicating improved chromatin stability. Taken together, the mitochondrial and chromatin measurements support coordinated regulation of the two systems rather than an effect confined to one pathway. The authors described R-glc as a functionally effective modulator of the mitochondria–chromatin axis with potential relevance to age-related functional decline, but that clinical potential remains unproven because the reported evidence comes from in-vitro research rather than human studies.

Subject of Research: In-vitro effects of resveratrol glucoside on mitochondrial function, chromatin regulation, and cellular senescence

Article Title: Resveratroloside alleviates senescence-associated phenotypes in vitro through the coordinated regulation of mitochondrial function and chromatin structure

Article References: Yoon, J. H., Kim, Y. H., Kim, D., Jeong, E. Y., Lee, S. H., Kim, H. Y., Park, J. H., So, M. K., Lee, Y. J., Kim, M., Song, J., Lim, S., Byun, Y., Shin, S. S., & Park, J. T. (2026). Resveratroloside alleviates senescence-associated phenotypes in vitro through the coordinated regulation of mitochondrial function and chromatin structure. Biogerontology, 27(6), Article 185. https://doi.org/10.1007/s10522-026-10532-y

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10532-y

Keywords: cellular senescence, resveratrol glucoside, mitochondrial function, chromatin regulation, SIRT6, histone acetylation, oxidative phosphorylation, in-vitro research, cell aging, Resveratroloside, alleviates, senescence-associated

Acute myeloid leukemia is a heterogeneous blood cancer in which genetic alterations, including mutations in DNMT3A, TET2, ASXL1 and IDH1 or IDH2, interact with dynamic changes in DNA methylation, histone marks, higher-order chromatin organization and gene expression. This combination sustains the capacity of malignant cells to self-renew, resist differentiation and move between transcriptional states. Because many epigenetic changes are reversible, they offer attractive therapeutic targets. Yet the same plasticity can let residual cells adapt, allowing pre-leukemic clones to survive and disease to relapse. The review therefore treats AML not as a collection of isolated molecular defects, but as a system in which relatively stable mutations establish a permissive framework that is continually reshaped by epigenetic regulation.

Hypomethylating agents such as azacitidine and decitabine were the first epigenetic drugs incorporated into routine myeloid treatment. They trap the DNA methyltransferase DNMT1 and promote passive loss of methylation during cell division, partially restoring silenced genes associated with differentiation and tumor suppression. Their principal role is disease modification rather than rapid elimination of leukemic blasts. The addition of venetoclax substantially improved remission and survival in the phase III VIALE-A trial for newly diagnosed patients unsuitable for intensive chemotherapy, but median survival was still measured in months rather than years, and outcomes varied with mutations such as NPM1, IDH1/2 and TP53. Failure is often linked to incomplete demethylation, compensatory methylation regulators, persistent founder clones and resilient leukemic stem-cell compartments, even when bulk blast measurements suggest a response.

Mutant IDH1 and IDH2 offer a more genetically defined route into the same methylation machinery. These enzymes produce the oncometabolite R-2-hydroxyglutarate, which inhibits TET enzymes and JmjC-domain histone demethylases, producing widespread hypermethylation and impaired myeloid differentiation. Ivosidenib and enasidenib demonstrated that suppressing this metabolite can restore differentiation, although responses are often incomplete and relapse remains common. The phase III AGILE trial subsequently showed that ivosidenib plus azacitidine improved event-free and overall survival over azacitidine alone in newly diagnosed, intensive-therapy-ineligible IDH1-mutant AML. Resistance nevertheless emerges through inhibitor-binding mutations, switching to the other IDH isoform, activation of proliferative signaling, altered metabolism and expansion of pre-leukemic or IDH-wild-type clones. Correcting metabolism can therefore create a differentiation window without removing every survival route.

Menin inhibitors attack a different regulatory layer by disrupting the KMT2A-menin complex, which sustains HOXA9 and MEIS1 programs in KMT2A-rearranged and NPM1-mutated disease. Revumenib, an oral menin inhibitor, produced complete remission or complete remission with partial hematologic recovery in roughly one fifth of evaluable patients in the phase I/II AUGMENT-101 trials, with some responders proceeding to allogeneic transplantation. It also illustrates the gap between molecular correction and clinical control. MEN1 mutations can impair revumenib binding, while TP53 inactivation may blunt apoptosis even when HOX and MEIS targets are successfully downregulated. Other work indicates that loss of PRC1.1 components can reactivate noncanonical targets such as MYC. Combination regimens are consequently being evaluated with hypomethylating agents, venetoclax, intensive chemotherapy and other targeted drugs, but longer follow-up is needed to establish durable benefit.

Several other chromatin targets remain investigational rather than established treatments. The DOT1L inhibitor pinometostat strongly suppressed H3K79 methylation yet produced few objective responses, apparently because some resistant cells continued to rely on DOT1L as a physical scaffold within the KMT2A complex rather than on its catalytic activity. Broad histone deacetylase inhibition has similarly been limited by a narrow therapeutic window and toxicity, encouraging interest in selective agents such as HDAC6 inhibitors. LSD1 inhibitors can promote myeloid maturation in models, but early clinical data remain limited and adaptive chromatin co-dependencies may undermine monotherapy. BET inhibitors have produced occasional responses while causing myelosuppression and other toxicities; preclinical studies show that rapid redistribution of the P300 acetyltransferase can preserve oncogenic transcription after BET blockade. Newer targets include PRMT5 in spliceosome-mutant disease and KAT6A/KAT7 in NUP98-rearranged leukemia, for which early clinical or preclinical evidence supports further biomarker-guided combination studies.

Non-coding RNAs provide another, still exploratory layer within these networks. Most act after transcription by promoting messenger RNA degradation, repressing translation or acting as molecular sponges, but selected long non-coding RNAs have been proposed to interact directly with chromatin regulators. HOTTIP is elevated in KMT2A-rearranged and NPM1-mutated models and has been reported to interact with WDR5/KMT2A complexes, helping maintain active chromatin at the HOXA locus. Disrupting HOTTIP in preclinical models reduced HOXA transcription, impaired clonogenic growth and prolonged survival. HOXA-AS2 has separately been proposed to recruit EZH2 and PRC2 to targets including LATS2, reinforcing repressive H3K27me3 chromatin. These observations remain context-dependent, and the specificity of many lncRNA-chromatin interactions is disputed. The review therefore does not classify non-coding RNAs as a separate epigenetic axis comparable to DNA methylation or histone modification.

Clinical translation of non-coding RNA biology is constrained by variable expression, functional redundancy among RNA family members, inconsistent results across cohorts and differences in samples, platforms and normalization methods. Delivering oligonucleotides or small interfering RNAs directly into leukemia cells also presents obstacles involving delivery, toxicity and compensation by parallel regulatory circuits. Their nearer-term value may therefore lie in measurement rather than direct treatment. HOXA-associated RNAs such as HOTTIP and HOXBLINC could potentially indicate how completely menin inhibition has silenced HOX loci, while other non-coding RNAs may help classify residual disease or track differentiation. These remain hypotheses requiring prospective testing alongside genomic, methylation and chromatin readouts, not established clinical markers.

The review’s central conclusion is that resistance in AML extends beyond ordinary drug failure or secondary mutations. Leukemic cells can preserve core survival programs by changing cofactors, reactivating alternative transcriptional circuits and maintaining epigenetic states in stem or progenitor compartments. This explains why strong laboratory activity has rarely translated into durable benefit in unselected patients, and why indiscriminate combinations have sometimes added toxicity without improving survival. Near-term progress is more likely through trials selected by molecular dependencies, combinations that address cooperating pathways, schedules designed around predictable adaptation, and single-cell multi-omics that distinguish temporary blast reduction from genuine reprogramming. Epigenetic therapy remains clinically actionable in AML, but its future depends on treating the network and measuring the state of its cells, rather than assuming that correcting one regulator is enough.

Subject of Research: Network redundancy, resistance mechanisms and non-coding RNA modulation in epigenetic therapy for acute myeloid leukemia

Article Title: Epigenetic therapy in AML: network redundancy, resistance, and non-coding RNAs

Article References: Fernandes, M. D. C. R., Scandolara, T. B., Mota, J. A., Manso, M. P., Furtado, G. P., Maranhão, S. S., Pessoa, C. D. Ó., & Furtado, C. L. M. (2026). Epigenetic therapy in AML: network redundancy, resistance, and non-coding RNAs. Epigenetics Communications, 6(1), Article 14. https://doi.org/10.1186/s43682-026-00054-6

Image Credits: AI Generated

DOI: 10.1186/s43682-026-00054-6

Keywords: acute myeloid leukemia, epigenetic therapy, DNA methylation, chromatin regulation, menin inhibitors, IDH inhibitors, hypomethylating agents, non-coding RNAs, drug resistance, cancer genomics, Epigenetic, therapy

BcEaf2 depletion selectively lowered the global level of trimethylation at histone H3 lysine 36, or H3K36me3, without measurably changing several other histone acetylation and methylation marks examined. The research focused on BcEaf2, a 568-amino-acid protein containing a conserved SANT domain that had been characterized in other eukaryotes as a component of chromatin-regulatory machinery. A genome-wide search identified the corresponding gene in B. cinerea, and phylogenetic analysis placed fungal and other animal homologs within a broader Eaf2/DMAP1 group.

Transcript measurements showed that BcEaf2 expression was developmentally regulated: its messenger RNA abundance was higher in conidia and during germination than in the mycelial baseline and rose further during host infection, with the highest levels reported at later invasion stages. Investigators screened more than 300 transformants in an attempt to create a homozygous BcEaf2 null mutant but did not recover one. Overexpression of BcEaf2 in one silenced strain largely restored wild-type growth, conidiation and stress tolerance, supporting a causal role for the targeted gene.

The absence of a specific antibody against endogenous BcEaf2 meant that the corresponding change in protein abundance could not be measured directly, an important limitation of the transcript-silencing approach. The silenced strains grew more slowly throughout measurements made one, three and six days after inoculation, rather than showing only a temporary developmental delay. By day six, wild-type, empty-vector and complemented colonies had covered the culture plates, whereas the silenced colonies had not.

Microscopy also revealed sparse networks with fewer branches and wider gaps between hyphae. On media containing hydrogen peroxide, potassium chloride or sorbitol, the silenced strains showed greater growth inhibition than the controls, indicating reduced tolerance to reactive oxygen species and osmotic pressure. A further assay with methyl methanesulfonate showed that all three silenced strains were more sensitive to DNA-damaging stress, while complementation restored tolerance.

Asexual reproduction was similarly impaired. Wild-type and empty-vector cultures produced abundant conidia, whereas each BcEaf2-silenced strain produced markedly fewer spores. Germ tubes emerged from more than 60% of spores in the control strains but fewer than 20% in the silenced strains.

Counts at seven and 11 days showed that the reduction persisted throughout the observation period, and reintroducing BcEaf2 largely restored conidial production. In the infection assay, the silenced strains caused substantially less tissue damage on detached Shine Muscat grapes. Confocal microscopy after wheat-germ agglutinin staining showed that their invasive hyphae rarely extended beyond the inoculation site, while fungal DNA measurements confirmed lower pathogen accumulation in infected tissue than after inoculation with wild-type or empty-vector controls.

Analysis of histone modifications revealed that BcEaf2 did not have a broad effect on every chromatin mark tested. Global levels of H3K18ac, H3K27ac and H4K5ac, as well as H3K4me3 and H3K27me3, were not significantly changed in the silenced strains under the in vitro conditions used. H3K36me3, however, was consistently and markedly reduced in all three mutants.

The selective biochemical phenotype connected BcEaf2 to the deposition of a specific histone mark rather than to a general increase or decrease in all forms of histone modification. The experiments measured global abundance in cultured mycelia; they did not map H3K36me3 to particular genes or establish the transcriptional targets responsible for the observed phenotypes. A yeast two-hybrid screen identified BcSET2, a protein containing the conserved SET catalytic domain associated with H3K36 methylation, as a BcEaf2 partner.

Targeted two-hybrid assays and co-immunoprecipitation confirmed the interaction, while deletion-mapping experiments showed that the SANT domain of BcEaf2 was required for binding in the two-hybrid system. Removal of the N-terminal or C-terminal regions did not significantly disrupt the association. The researchers could not recover a stable BcEaf2 mutant lacking the SANT domain, however, so the domain’s direct contribution to H3K36me3 regulation could not be tested in a deletion strain.

BcSET2 messenger RNA abundance did not differ significantly between the BcEaf2-silenced strains and the wild type under the tested conditions. That measurement showed no detectable change in BcSET2 transcription, but it did not identify the molecular basis of the protein interaction. Purified recombinant proteins provided a biochemical test of the proposed mechanism.

BcSET2 exhibited intrinsic H3K36 methylation activity in vitro, and adding BcEaf2 markedly increased the amount of H3K36me3 deposited. BcEaf2 stimulated wild-type BcSET2 in a dose-dependent manner. By contrast, a catalytic-deficient BcSET2 variant with the conserved NHXCXPN motif removed showed markedly reduced activity and was not detectably stimulated by BcEaf2.

Comparable protein abundance in the wild-type and catalytic-deficient preparations argued against the activity difference simply reflecting unequal BcSET2 abundance. The results therefore support BcEaf2 as a positive regulator of BcSET2-dependent H3K36me3 formation, although the assays do not establish whether the cofactor stabilizes the enzyme, improves substrate recognition, promotes an active conformation or influences recruitment to chromatin. Deleting BcSET2 produced the same broad phenotype previously associated with BcEaf2 silencing.

Three independent knockout strains had reduced radial growth, sparse hyphae, greater sensitivity to hydrogen peroxide, potassium chloride, sorbitol and methyl methanesulfonate, and sharply reduced conidiation. Fewer than 20% of their conidia germinated, compared with more than 60% in wild-type, empty-vector and complemented strains. The knockouts also caused weaker lesions on grape berries, showed limited invasive hyphal expansion and accumulated less fungal biomass in infected tissue.

Genetic complementation restored these traits toward wild-type levels. The parallel results support functional coupling between BcEaf2 and BcSET2, but they do not by themselves prove that every phenotype is caused exclusively by reduced H3K36me3 rather than by additional molecular effects of these proteins. Overall, the study presents BcEaf2 and BcSET2 as a regulatory module that connects histone H3 lysine 36 trimethylation with fungal fitness and pathogenicity in B. cinerea.

The findings extend the known repertoire of Eaf2/DMAP1 proteins beyond their better-characterized roles in DNA methylation maintenance or histone acetylation in mammals and yeast, showing that the fungal homolog can instead enhance a histone methyltransferase. The work also illustrates why null mutants are informative: repeated failures to obtain BcEaf2 knockouts and SANT-domain deletions suggest severe consequences for viability or transformant recovery, although that interpretation remains inferential. Because the virulence tests used wounded detached grapes under controlled laboratory conditions and the methyltransferase evidence came from purified proteins, the results do not establish field disease control, clinical benefits or an effective antifungal treatment.

They instead identify a mechanistic target for future research that would require chromatin mapping, structural analysis, proteomics and testing across additional fungal species.

Subject of Research: Molecular regulation of fungal growth and virulence by the BcEaf2–BcSET2 histone-methylation module in Botrytis cinerea

Article Title: BcEaf2 plays a critical role in hyphal growth, asexual reproduction, pathogenic infection, and histone methylation in Botrytis cinerea

Article References: Wu, J., Wu, W., Wu, Y., Hao, J., Chen, W., Wang, H., Yang, C., & Shen, F. (2026). BcEaf2 plays a critical role in hyphal growth, asexual reproduction, pathogenic infection, and histone methylation in Botrytis cinerea. Frontiers in Microbiology, 17, Article 1978891. https://doi.org/10.3389/fmicb.2026.1978891

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1978891

Keywords: Botrytis cinerea, BcEaf2, BcSET2, H3K36me3, histone methylation, fungal virulence, plant pathology, chromatin regulation, fungal stress response, asexual reproduction, plays, critical

Histone deacetylases, or HDACs, are among the most conserved epigenetic regulators in biology. By removing acetyl groups from lysine residues on the N-terminal tails of histones H2A, H2B, H3, and H4, they establish transcriptionally repressive chromatin states. In fungi, these enzymes fall into three broad classes based on their yeast counterparts: zinc-dependent Class I RPD3-type enzymes, zinc-dependent Class II HDA1-type enzymes, and NAD+-dependent Class III enzymes known as sirtuins. Previous work in other fungi has shown that Class I members govern growth and virulence, Class II members are indispensable for host colonization and stress tolerance, and sirtuins regulate asexual development, nutrient utilization, and resistance to thermal and ultraviolet stress.

Using the genome of the F. oxysporum strain Fo47 as a starting point, the team searched NCBI and UniProt databases with hidden Markov models built on conserved HDAC and sirtuin domain profiles, applying a stringent significance threshold. The search identified exactly 11 FoHDAC genes. Phylogenetic reconstruction, comparing the fungal sequences with reference HDACs from budding yeast, Arabidopsis, and humans, sorted the family into three subfamilies: two Class I genes, two Class II genes, and a strikingly dominant SIR2 subfamily containing seven members. That expansion of the sirtuin clade stands out, because related fungi such as Alternaria alternata and Candida albicans carry only six to eight HDAC genes in total.

Structural analysis reinforced the phylogenetic picture. Three-dimensional alignments in PyMOL yielded root-mean-square deviation values between FoHDACs and their orthologs ranging from 0.312 to 3.397 angstroms. One protein, corresponding to FoRPD3, showed exceptional structural similarity to yeast RPD3, with a conserved catalytic pocket geometry that validated the evolutionary clustering. Another, FoClr3, diverged more substantially from yeast HDA1 yet retained its critical active-site residues, a pattern the authors interpret as structural plasticity that may facilitate functional adaptation to environmental pressures. Motif analysis with the MEME Suite uncovered ten conserved signatures, with Class I and II enzymes universally sharing Motifs 3 and 5, while sirtuins uniformly retain Motifs 1, 2, 4, 6, and 8, hinting at deep evolutionary conservation of their catalytic cores.

Physicochemical profiling revealed a family of considerable diversity. Protein lengths ranged from 298 to 1,087 amino acids, corresponding to molecular masses between roughly 32.8 and 117.8 kilodaltons, and isoelectric points split the family into acidic, basic, and near-neutral members. Subcellular localization predictions placed six proteins in the nucleus, three in the cytoplasm, and two, FoSIR5 and FoSIR4, in mitochondria, indicating that the family’s regulatory reach extends across organelles. All members were hydrophilic, and the team observed a significant negative correlation between hydrophilicity and aliphatic index, suggesting that reduced non-polar amino acid content enhances solubility and may favor protein-nucleic acid interactions.

Chromosomal mapping showed the 11 genes distributed asymmetrically across six chromosomes, with chromosomes 1 and 4 each hosting three genes, chromosome 8 two, and chromosomes 5 and 12 one apiece, while six chromosomes carried none at all. Synteny analysis ruled out recent segmental duplications as drivers of family expansion, pointing instead to functional specialization as the route to diversification. Comparative genomics across Fusarium graminearum and Fusarium solani revealed strict one-to-one orthology for all 11 genes, but only three sirtuin-class genes showed cross-family orthology with the rice blast fungus Magnaporthe oryzae, underscoring the exceptional conservation of core sirtuin machinery across fungal lineages.

The promoter regions upstream of the FoHDAC genes proved to be dense with regulatory information. Screening 2-kilobase stretches identified 22 putative cis-regulatory elements, including core motifs such as CAAT and TATA boxes alongside antioxidant response elements ARE and as-1, stress response elements known as STRE, dehydration-responsive DRE elements, MYB and MYC recognition sites, and W-boxes targeted by WRKY transcription factors. The as-1 motif was conserved across every family member, pointing to essential roles in mitigating oxidative stress, while selective enrichment of WRE elements in specific genes suggested spatiotemporal specialization for developmental coordination. In essence, the promoters are wired to translate environmental signals, from reactive oxygen species to osmotic shifts, into rapid epigenetic reconfiguration.

Gene Ontology enrichment and molecular docking simulations then connected structure to function. Beyond core deacetylation, the genes were annotated for roles in transcriptional regulation, macromolecular catabolism, and heterochromatin assembly, with FoHST4, FoHST3, and FoClr3 implicated in cellular component organization relevant to sporulation and cell wall biogenesis. Docking against eight histone acetylation marks, including H3K9ac and H4K16ac, produced robust binding affinities at or below minus 5 kilocalories per mole for all FoHDACs. The HDAC-class enzymes employed conserved His/Asp catalytic dyads with distinct substrate preferences, FoHOS3 selectively engaging H4K16ac and FoClr3 targeting multiple sites, while sirtuins displayed broader recognition, with FoHST3 binding every tested site and FoSIR2 showing high affinity for H3K14ac and H3K23ac. Notably, FoHST4, FoHST3, and FoSIR2 also exhibited intrinsic histone acyltransferase activity, marking them as bifunctional enzymes.

Expression profiling by reverse-transcription quantitative PCR across four developmental stages revealed choreographed dynamics. Eight genes peaked in the dormant conidial phase, were suppressed during spore germination, and progressively recovered through mycelial growth and sporulation, while FoHOS3 and FoRPD3 were continuously activated across developmental transitions and FoSIR7 was induced exclusively during sporulation. Under stress, the picture sharpened dramatically. Salt stress broadly repressed transcription, most dramatically a 33.67-fold suppression of FoHST3, whereas cold stress at 4 degrees Celsius triggered an induction of FoHOS3 exceeding 100-fold, accompanied by coordinated activation of FoHOS2, FoRPD3, and FoSIR7. Heat stress upregulated FoHOS3 more than 15-fold, oxidative stress elevated FoHOS3, FoSIR7, and FoSIR5, and fungicide exposure produced compound-specific responses, with fludioxonil activating FoHOS3 and FoSIR7 and hymexazol inducing FoSIR7, FoHST2, and FoSIR5.

Taken together, the findings cast FoHOS3 as a master stress integrator, consistently induced across osmotic, oxidative, thermal, and chemical challenges, with FoSIR7 acting as a broad-spectrum responder and FoHST3 and FoHST4 typically repressed under stress. The authors propose a three-phase epigenetic model of pathogenic progression, spanning dormancy governed by FoHOS2 and FoClr3, virulence activation, and colonization driven by FoSIR7. Because HDACs are dispensable or divergent between fungi and their hosts, the family represents an attractive target for next-generation fungicides designed to disrupt virulence with minimal off-target effects. The team notes that future work combining chromatin accessibility and histone modification mapping will be needed to fully resolve the regulatory networks, but the study establishes a foundation for precision antifungal strategies at a time when climate-stressed agriculture urgently needs them.

Subject of Research: Genome-wide identification and expression profiling of histone deacetylase genes in the plant-pathogenic fungus Fusarium oxysporum

Article Title: Genome-wide identification and expression profiling of the histone deacetylase gene family in Fusarium oxysporum

Article References: Liao, H.-X., Wen, J.-R., Shi, H.-M., Cun, H.-Q., Hong, Y.-J., Hu, Z.-F., Xu, F.-R., Noiprasert, S., Apiwongsrichai, K., Liu, X.-Y., & Dong, X. (2026). Genome-wide identification and expression profiling of the histone deacetylase gene family in Fusarium oxysporum. IMA Fungus, 17, Article e168980. https://doi.org/10.3897/imafungus.17.168980

Image Credits: AI Generated

DOI: 10.3897/imafungus.17.168980

Keywords: Fusarium oxysporum, histone deacetylases, epigenetics, sirtuins, plant pathology, chromatin regulation, gene expression, molecular docking, stress response, fungicides, vascular wilt, genomics

Medulloblastoma arises in the cerebellum and comprises four major molecular subgroups: WNT, SHH, Group 3, and Group 4. While WNT tumors have an excellent prognosis and SHH tumors can sometimes be addressed with inhibitors of the sonic hedgehog pathway, Group 3 and Group 4 remain stubbornly resistant to targeted approaches. Children with these tumors typically receive maximal surgery, craniospinal irradiation, and multi-agent chemotherapy. Although survival rates have improved over decades, the intensity of treatment leaves many survivors with lasting cognitive, endocrine, and developmental damage. This therapeutic gap is precisely what motivated the St. Jude and KiTZ collaboration: if no drugs exist for these subgroups, the field must first discover what the tumors cannot live without.

The biological logic behind the search lies in epigenetics. Epigenetic regulation refers to the layer of control that determines which genes are switched on or off without altering the underlying DNA sequence. The principal players are chemical marks deposited on histones, the protein spools around which DNA is wound. Distinct histone modifications, such as methylation and acetylation at specific amino acid positions, act as signposts that recruit or repel the molecular machinery of transcription. Because epigenetic deregulation that disrupts normal brain development has long been suspected of driving medulloblastoma formation, mapping the exact histone modification landscape of patient tumors promised to reveal where that control breaks down, and which proteins might be holding the broken system together.

Delivering that map required an effort of unusual scale for a rare pediatric cancer. The team performed the largest analysis of its kind in medulloblastoma, profiling 52 primary patient samples drawn from all four major subgroups, with multiple samples per subgroup to ensure that subgroup-specific signals could be distinguished from individual tumor quirks. They measured six distinct histone post-translational modifications and used chromatin state, the functional packaging configuration of the genome, as a readout of epigenetic activity. The resulting dataset, made publicly available through a web portal so that other investigators can mine it, constitutes a comprehensive community resource. The researchers deliberately designed the resource to help the field move beyond cataloging mutations toward identifying functional dependencies.

The search for strong subgroup-specific signals quickly paid off. The team detected a recurrent, aberrant epigenetic signature shared by Group 3 and Group 4 tumors, an unexpected convergence given that these subgroups differ in their genomic features and presumed cells of origin. When the researchers asked which chromatin-modifying protein could account for the signature, KDM2B emerged as the leading candidate. First author Ran Tao, PhD, of the St. Jude Department of Developmental Neurobiology described the progression: after identifying the signature, the team spent years investigating how KDM2B controls tumor growth and working through the underlying molecular mechanisms. KDM2B is highly expressed in Group 3 and Group 4 tumors, and its abundance marks it as a defining feature of these high-risk disease categories.

Functionally, KDM2B proved to be a genuine dependency rather than a passive passenger. In preclinical models, genetic removal of the KDM2B gene or pharmacologically oriented degradation of the protein suppressed tumor growth and extended survival. Corresponding author Paul Northcott, PhD, director of the St. Jude Center of Excellence in Neuro-Oncology Sciences and a member of the Department of Developmental Neurobiology, summarized the finding: select medulloblastoma groups require KDM2B to grow, which gives the field a potential future therapeutic opportunity to selectively suppress the growth of Group 3 and Group 4 tumors while sparing normal tissue. The selectivity is the crucial point, because an ideal pediatric target should be dispensable in healthy cells but indispensable in the tumor.

The project itself has a long history that illustrates how cancer genomics matures over time. Northcott traced its origins to his postdoctoral years, when early sequencing of medulloblastoma genomes revealed an enrichment of alterations in chromatin-modifying genes, a signal that at the time had no obvious therapeutic exploitation. Almost fifteen years later, with modern epigenomic profiling tools and the infrastructure to study dependencies, that old signal could finally be pursued to its mechanistic roots. The trajectory underscores a broader lesson in pediatric oncology: discoveries from large-scale sequencing projects often take years, sometimes decades, before they translate into actionable biology, and sustained investment in data generation and model systems is what makes such translation possible.

KDM2B itself is not the end of the story, and perhaps not even the easiest drug target. The mechanistic studies showed that KDM2B exerts its growth-promoting influence by recruiting Polycomb repressive complexes, a family of protein assemblies that modify chromatin to silence genes. Recognizing this downstream dependency, the team looked for additional vulnerabilities among the complexes themselves. Data from The Pediatric Cancer Dependencies Accelerator, a multi-institutional initiative involving the Broad Institute, Dana-Farber Cancer Institute, and St. Jude, indicated that removing these Polycomb complexes in medulloblastoma cell lines also slows cancer growth. This downstream angle matters clinically because drugging a complex can be more tractable than drugging a single regulatory protein.

Two Polycomb-related findings stand out for their therapeutic implications. First, PRC2, one of the Polycomb repressive complexes, is already being investigated as a drug target in other pediatric cancers, which lends external validation to the strategy and suggests that existing medicinal chemistry and clinical experience could be adapted for medulloblastoma trials. Second, the study identified PRC1.1 as a previously unrecognized potential therapeutic target for Group 3 and Group 4 medulloblastoma, adding a novel candidate to a therapeutic landscape that previously held none. Together, these findings reframe the problem: targeting KDM2B directly, or disrupting the Polycomb pathways it recruits, provides at least three distinct intervention points against tumors that have historically been treated with one-size-fits-all regimens.

The researchers emphasize that the public dataset is as much a product of the study as the KDM2B discovery itself. By characterizing the medulloblastoma chromatin landscape in unprecedented detail and making it freely explorable, the team hopes that other laboratories will mine the resource for additional subgroup-specific signatures and dependencies. Northcott framed the ambition plainly: the characterization identified a potential vulnerability in subgroups that still lack targeted therapy, and he hopes others will explore the data to make further discoveries and, collectively, find new therapeutic targets for subgroups with poor prognosis. For the children diagnosed with Group 3 and Group 4 medulloblastoma each year, the study converts fifteen years of accumulated genomic insight into a concrete biological target, a set of downstream pathway candidates, and a roadmap for developing the selective treatments that this high-risk population has long awaited.

Subject of Research: KDM2B dependency in Group 3 and Group 4 medulloblastoma epigenetics

Article Title: KDM2B revealed as a selective dependency in high-risk medulloblastoma subgroups

Article References: KDM2B revealed as a selective dependency in high-risk medulloblastoma subgroups. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: medulloblastoma, KDM2B, epigenetics, histone modifications, Polycomb repressive complexes, Group 3 medulloblastoma, Group 4 medulloblastoma, pediatric brain tumor, targeted therapy, chromatin regulation, PRC2, preclinical models

The clinical starting point came from three patients with neurodevelopmental disorders who carried damaging MSL2 variants. Two harbored protein-truncating variants, one a de novo frameshift and one a stop-gain mutation with undetermined inheritance, while the third carried a de novo 83-kilobase microdeletion spanning both MSL2 and the neighboring PCCB gene. All three children presented with moderate to severe intellectual disability, language impairment, and motor delay, and two showed autism or autistic features. Critically, magnetic resonance imaging revealed white matter abnormalities in every patient, ranging from a thin corpus callosum and punctate frontal hyperintensities in the oldest patient to diffuse symmetrical T2 hyperintensity, ventricular enlargement, and widespread polymicrogyria in a seven-month-old infant. The consistency of these imaging findings across patients with different mutation types underscored white matter vulnerability as a hallmark of MSL2-related disease.

To probe what the variants actually do to cells, the team turned to immortalized lymphocytes available from the patient carrying the microdeletion. Western blotting and immunofluorescence showed markedly reduced MSL2 protein compared with four age- and sex-matched healthy controls, and the levels of two histone marks that MSL2 helps regulate, H4K16ac and H3K4me3, trended downward in the patient’s cells. These marks are chemical embellishments on histone proteins that flag chromatin as open and transcriptionally active, so their reduction signaled that the mutation genuinely impairs MSL2’s epigenetic function rather than merely removing one copy of the gene. The finding gave the researchers a molecular fingerprint to hunt for in the brain.

That hunt required a new animal model, because mice lacking Msl2 from conception die as embryos, masking any role the gene plays in specific cell types. The team instead crossed mice carrying a floxed Msl2 allele with Olig1-Cre mice, deleting a critical exon that encodes both the N-terminal RING finger domain and the C-terminal CXC domain, thereby producing a loss-of-function mutation exclusively in the oligodendrocyte lineage. Quantitative PCR and western blotting confirmed that Msl2 expression collapsed in purified precursor cells from these conditional knockouts, while MSL2 protein remained intact in mature neurons, proving the deletion was cell-type specific. The researchers also tracked where and when MSL2 acts normally, finding that Msl2 transcripts were far more abundant in white matter structures such as the corpus callosum and optic nerve than in cortex at postnatal day 7, peaked in the first two postnatal weeks, and were highest in newly formed oligodendrocytes before declining in mature myelin-producing cells.

What happened when the gene was removed was striking. The density of SOX10-positive oligodendrocyte lineage cells was normal at birth but fell significantly from postnatal day 7 through day 50 in both the corpus callosum and the cortex. The proportion of CC1-positive mature oligodendrocytes dropped, myelin basic protein levels declined sharply, and electron microscopy at postnatal day 40 revealed fewer myelinated axons with thinner myelin sheaths and higher g-ratios, a quantitative measure of reduced myelin thickness. TUNEL assays ruled out increased cell death, but EdU incorporation showed far fewer proliferating precursor cells in the mutants, and fewer of the cells that did incorporate EdU went on to become MBP-positive oligodendrocytes. In purified cultures treated with thyroid hormone to drive differentiation, Msl2-deficient cells showed intrinsically reduced capacity to become CNPase- and MBP-positive oligodendrocytes, and an inducible knockout triggered at the onset of differentiation still impaired maturation, indicating that MSL2 is required both for proper cell division and for the initiation of differentiation.

The behavioral fallout mirrored the cellular damage. In the three-chamber sociability test, mutant mice showed no preference for a stranger mouse over an empty chamber and failed to recognize social novelty, while the resident-intruder test revealed strong social avoidance and the self-grooming test revealed repetitive behavior, together recapitulating the core diagnostic domains of autism spectrum disorder. Open field and elevated plus maze tests showed heightened anxiety, the tail suspension test and sucrose preference test indicated depressive-like states, and notably, novel object recognition remained intact, suggesting that cognition was spared even as social and emotional behaviors were disrupted. This constellation of social withdrawal, repetitive grooming, and comorbid anxiety and depression makes the conditional knockout a potentially valuable model for studying how epigenetically regulated myelin contributes to autism.

The mechanistic core of the study came from integrated transcriptomic and epigenomic profiling of purified precursor cells. RNA sequencing identified 1,166 genes upregulated and 327 downregulated after Msl2 loss, and gene ontology analysis of the downregulated set pointed squarely at cell cycle, cell division, mitotic spindle, and myelin sheath terms. Among the affected genes were Aspm, a microcephaly-associated spindle assembly factor; Tpx2, which nucleates spindle microtubules; and Bub1b, a kinase essential for the spindle-assembly checkpoint. Cell synchronization experiments made the consequence concrete: while nearly 70 percent of phospho-histone H3-positive control cells reached metaphase, only about 25 percent of mutant cells did, with most stalling in prophase or prometaphase and metaphase cells displaying loose chromosome compaction, triple or multipolar spindles, and twisted spindle architectures. Meanwhile, the upregulated genes were enriched for inflammatory response, innate immune response, and cytokine activity, with chemokines such as Cxcl1, Cxcl2, Ccl4, and Ccl20 elevated, hinting that MSL2 loss may endow precursor cells with immunomodulatory properties that could exacerbate neuroinflammation.

Epigenomic mapping revealed which histone mark carries the weight. ChIP-seq for H3K4me3 showed that although the genomic distribution of peaks was broadly preserved, peak signals dropped dramatically near transcription start sites after Msl2 deletion, and genes losing the mark were enriched for myelination, oligodendrocyte differentiation, cell proliferation, and mitotic G2/M transition terms. Cross-referencing with the transcriptome showed that 177 genes with reduced H3K4me3 were also transcriptionally downregulated, accounting for nearly 36 percent of all downregulated genes. By contrast, H4K16ac, the canonical product of the MSL-MOF complex, was only mildly reduced and overlapped with just 12 percent of downregulated genes, while H2BK120ub, an indirect target of MSL2’s ubiquitin ligase activity, showed minimal concordance with either H3K4me3 loss or transcriptional change. The data collectively reposition H3K4me3, rather than H4K16ac, as the dominant downstream effector of MSL2 in oligodendrocyte lineage cells.

Proteomics added an unexpected twist to the mechanism. Co-immunoprecipitation coupled with mass spectrometry identified 160 MSL2-interacting proteins in precursor cells, including the expected partner KAT8, also known as MOF, but also ASH2L and RBBP5, the core subunits of the COMPASS-like H3K4 methyltransferase complex, and SOX10, the master transcription factor of the oligodendrocyte lineage. Western blotting on MSL2 immunoprecipitates validated all of these interactions. This suggests a previously unrecognized model in which MSL2 physically recruits the H3K4 methylation machinery to myelination and cell cycle genes, with SOX10 potentially guiding the complex to its oligodendrocyte-specific targets, independent of MSL2’s E3 ubiquitin ligase activity toward H2B.

The implications extend well beyond a rare syndrome. Because MSL2 governs the transition from proliferating precursor cells to differentiating oligodendrocytes rather than lineage commitment itself, modulating MSL2 complex activity could, in principle, enhance myelination programs not only in MSL2-related neurodevelopmental disorders but also in conditions involving demyelination. The study’s authors caution that more than 60 percent of downregulated genes did not show significant H3K4me3 reduction, leaving room for additional mechanisms such as H3K79 methylation or MSL2’s proposed role in protecting regulatory regions from DNA methylation. Still, by linking patient genetics, cell-autonomous mouse genetics, cell cycle biology, and chromatin profiling into a single coherent story, the work transforms MSL2 from a gene of uncertain function into a defined epigenetic regulator of the brain’s insulation, and it offers the white matter defects seen on MRI in affected children their first clear molecular explanation.

Subject of Research: The role of the chromatin regulator MSL2 in oligodendrocyte precursor cell cycle control, H3K4me3-mediated gene regulation, and white matter defects in neurodevelopmental disorders.

Article Title: MSL2 orchestrates oligodendrocyte precursor cell cycle via H3K4me3 to prevent white matter defects in neurodevelopmental disorders

Article References: Yuan, J., Dong, Y., Zhang, K., Wei, Z., Zhang, Z., Zhang, M., Luo, S., Jiang, S., Peng, Y., Wu, X., Yvan, H., Goel, H., Zhang, E., The Australian Undiagnosed Diseases Network (UDN-Aus), Guo, H., Wu, S., & Zhao, X. (2026). MSL2 orchestrates oligodendrocyte precursor cell cycle via H3K4me3 to prevent white matter defects in neurodevelopmental disorders. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01858-1

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01858-1

Keywords: MSL2, oligodendrocytes, H3K4me3, myelination, neurodevelopmental disorders, autism spectrum disorder, white matter, epigenetics, cell cycle, mitotic spindle, conditional knockout mice, chromatin regulation

The research, led by Hua Jing and Yingli Zhang at Xinyang Agriculture and Forestry University in Henan, China, builds directly on the team’s earlier finding that the chromatin-associated protein ALFIN1-LIKE 6, or AL6, is modified by SUMOylation, a process in which small ubiquitin-related modifier (SUMO) peptides are attached to target proteins. In their previous work, the researchers showed that the SUMO E3 ligase SIZ1 attaches SUMO to AL6 and that this modification participates in regulating seed dormancy. What remained unknown was the reverse step: which enzyme removes the tag, and what consequences that removal has for the seed.

The answer, according to the new paper, is ARABIDOPSIS SUMO PROTEASE 1, known as ASP1. SUMO proteases are the scissors of the SUMO system, cleaving the modifier back off target proteins and thereby reversing the effects of SUMOylation. The team demonstrates that ASP1 physically interacts with AL6 and mediates its deSUMOylation. Crucially, this enzymatic activity is not a side detail: the study shows that ASP1’s SUMO protease function is required for its role in controlling seed dormancy, tying the enzyme’s catalytic behavior directly to a developmental outcome.

What makes the finding conceptually elegant is the chain of consequences that follows the removal of the tag. The researchers report that ASP1-mediated deSUMOylation promotes the degradation of the AL6 protein. At the same time, it reduces AL6’s association with the genomic locus of DELAY OF GERMINATION 1, or DOG1, the master regulator of primary seed dormancy in Arabidopsis. In other words, stripping the SUMO tag does two things at once: it shortens AL6’s lifespan and loosens its grip on the DNA region it influences. Both effects converge on the same target, modulating DOG1 expression and, through it, the depth of dormancy that a freshly harvested seed establishes.

DOG1 is one of the most celebrated genes in seed biology. Cloned more than a decade ago as a quantitative trait locus controlling dormancy, it has been shown in numerous studies to act as a central hub integrating hormonal, environmental, and developmental cues. The amount of DOG1 protein in freshly harvested seeds largely determines how long a seed must rest before it will germinate. Because DOG1 expression is controlled at many levels, including transcription factors, chromatin state, and antisense transcripts, the discovery that a SUMOylation cycle feeds into this control network adds a dynamic, reversible layer to what scientists already knew.

AL6 belongs to the ALFIN1-like family of plant homeodomain finger proteins, a class of nuclear proteins known to bind histone marks such as H3K4me3 and to participate in chromatin-level regulation. Previous work has implicated AL family members in processes ranging from root hair elongation during phosphate deficiency to the chromatin switching that governs seed germination genes. The new study positions AL6 as a chromatin-associated factor whose stability and DNA occupancy are tuned by the SUMO cycle, offering a concrete example of how post-translational modification can link protein turnover to gene regulation in seeds.

The mechanistic logic of the system is worth unpacking. When AL6 is SUMOylated, the modification appears to stabilize the protein and support its association with the DOG1 locus, allowing AL6 to influence DOG1 transcription. When ASP1 removes the SUMO tag, AL6 becomes less stable and is degraded, and whatever remains loses its affinity for the DOG1 genomic region. The result is a shift in DOG1 expression and, consequently, in the seed’s propensity to remain dormant. This kind of dual action, affecting both protein abundance and chromatin association through a single enzymatic event, illustrates why SUMOylation has become a focus of research into rapid, reversible control of plant development.

ASP1 itself has an interesting track record. Earlier studies had shown that it positively regulates flowering time partly through stability of the floral repressor FLC, and that it participates in abscisic acid signaling during early seedling development. The new work extends its portfolio into seed dormancy and clarifies that its protease activity, rather than some non-catalytic scaffolding role, is what matters for the dormancy phenotype. The authors also note that ASP1 interacts with and deSUMOylates AL7, a close relative of AL6, suggesting that the enzyme’s reach within the ALFIN1-like family may be broader than a single target, although the functional consequences for AL7 in seeds remain to be fully explored.

Importantly, the regulation appears to operate at the protein level rather than the transcript level. The study’s supporting data indicate that ASP1 does not alter the messenger RNA levels of AL6 or AL7 in freshly harvested seeds, pointing instead to a post-translational mechanism. This distinction matters for how the pathway might ultimately be manipulated: interventions targeting SUMO protease activity or the stability of SUMOylated chromatin factors could, in principle, tune dormancy without changing the underlying genetic program, a feature that is attractive for crop improvement where dormancy traits are often polygenic and environmentally sensitive.

The broader significance of the work lies in completing a reversible cycle. SIZ1 writes the SUMO mark on AL6; ASP1 erases it. Together they form a push-pull system that can respond to developmental and environmental signals by adjusting AL6 protein levels and chromatin occupancy in real time. As the authors conclude, ASP1-mediated deSUMOylation of AL6 is an important post-translational regulatory mechanism linking AL6 protein stability and chromatin association to DOG1 expression and the establishment of primary seed dormancy. For a trait as economically consequential as dormancy, which shapes everything from seed banking to pre-harvest sprouting in cereals, uncovering the enzymes that write and erase regulatory marks on dormancy genes is a step toward understanding, and eventually managing, one of biology’s most consequential waiting games.

Subject of Research: ASP1-mediated deSUMOylation of the chromatin protein AL6 and its role in regulating DOG1 expression and primary seed dormancy in Arabidopsis thaliana

Article Title: ASP1-mediated deSUMOylation of AL6 controls seed dormancy in Arabidopsis

Article References: Jing, H., Li, C., & Zhang, Y. (2026). ASP1-mediated deSUMOylation of AL6 controls seed dormancy in Arabidopsis. Plant Cell Reports, 45(10), Article 281. https://doi.org/10.1007/s00299-026-03964-w

Image Credits: AI Generated

DOI: 10.1007/s00299-026-03964-w

Keywords: seed dormancy, Arabidopsis, SUMOylation, deSUMOylation, ASP1, SUMO protease, AL6, DOG1, chromatin regulation, post-translational modification, plant molecular biology, SIZ1

The central finding of the study is deceptively simple to state: when a specific distal regulatory region controlling IRF4 is deleted, inflammation-induced reprogramming of human regulatory T cell fate is prevented. In other words, this remote stretch of DNA, located far from the IRF4 gene itself, acts as a control hub for the transcriptional machinery that responds to inflammatory cues. Distal regulatory elements such as enhancers and silencers do not encode proteins; instead, they serve as landing platforms for transcription factors and co-regulators that physically loop through three-dimensional chromatin space to contact gene promoters. The element characterized by Tang and colleagues appears to be exactly this kind of architectural and regulatory module, channeling inflammatory signals into IRF4 expression and thereby into the downstream fate decisions of the cells.

IRF4, or interferon regulatory factor 4, is a transcription factor with a well-established reputation in immunology. It is induced in lymphocytes following antigen receptor signaling and is known to shape differentiation programs in effector T cells, B cells, and myeloid populations. In regulatory T cells, IRF4 has been implicated in contexts where these cells operate in inflammatory environments, where they may need to adapt their suppressive functions to rein in strongly activated immune responses. What the new study adds is a human-specific, chromatin-level view of how IRF4’s involvement is wired: not through the core promoter alone, but through a distal element whose activity is responsive to the inflammatory milieu. Deleting this element uncouples inflammation from IRF4-driven fate reprogramming, effectively locking the cells into their regulatory identity.

The experimental strategy behind the finding reflects the current generation of human immunology research, which increasingly combines genome editing with high-resolution chromatin and transcriptome profiling. Although the authors’ precise experimental design follows the conventions of modern chromatin biology, the conceptual logic can be described clearly. Candidate regulatory elements near IRF4 are identified through chromatin accessibility and histone modification signatures that mark active enhancers. Such elements are then perturbed, in this case through deletion, and the consequences are measured in human regulatory T cells exposed to inflammatory conditions. By comparing edited and unedited cells, the researchers could ask directly whether the distal element is necessary for the inflammatory reprogramming program to proceed. The answer was emphatic: without it, the reprogramming does not occur.

This result carries substantial weight for a long-running debate in T cell biology: the question of Treg stability. Regulatory T cells express the master transcription factor FOXP3, which orchestrates their suppressive gene program, and for years researchers have asked whether FOXP3 expression and the regulatory identity it confers are permanent or plastic. Mouse models demonstrated decades ago that loss of FOXP3 in mature Tregs can convert them into effector-like cells that promote, rather than restrain, autoimmunity. Human data have been more complicated, in part because human Tregs are heterogeneous and because the inflammatory conditions they encounter in tissues differ from those in laboratory mice. The new study provides a human-data anchor for this debate, pinpointing a regulatory DNA element whose integrity is required for inflammation to even attempt a fate conversion.

Why would the immune system build such a vulnerable-looking circuit in the first place? The authors’ findings suggest a nuanced answer. IRF4-mediated reprogramming of regulatory T cells in inflammatory settings may not be purely pathological. In inflamed tissues, Tregs face extraordinary demands: they must suppress responses driven by potent cytokine environments while surviving in conditions that would exhaust or redirect ordinary lymphocytes. Allowing a controlled degree of plasticity, mediated by IRF4, could help Tregs adjust their suppressive repertoire to the inflammatory context. The distal IRF4 element, in this framing, is less a weakness than a tunable valve. Its deletion prevents reprogramming entirely, which reveals the mechanism but also raises the question of what beneficial functions the reprogramming serves when the element is intact.

At the same time, the pathological potential of Treg plasticity is well recognized. In autoimmune diseases, chronic inflammatory environments have been associated with Treg populations that lose suppressive function or acquire effector characteristics, contributing to a vicious cycle in which the very cells meant to dampen inflammation instead fuel it. Similarly, in cancer biology, regulatory T cells infiltrating tumors often display IRF4-associated transcriptional features as they adapt to the tumor microenvironment. The identification of a distal chromatin element as the gatekeeper of this process therefore has implications that extend well beyond basic developmental biology. It suggests a specific, addressable node in the genome where the balance between Treg stability and plasticity might be therapeutically adjusted.

From a therapeutic standpoint, the study’s implications are intriguing but must be interpreted with care. Autoimmune disease, where the goal is to strengthen Treg stability, could in principle benefit from approaches that dampen the activity of the IRF4 distal element or its downstream program, preserving suppressive function in the face of chronic inflammation. Cancer immunotherapy points in the opposite direction: if tumor-infiltrating Tregs rely on this regulatory circuit to adapt and persist, interfering with the element might render tumor-associated Tregs less fit and thereby enhance antitumor immunity. However, IRF4 is essential for multiple immune cell types, and globally targeting it or its regulatory element would carry broad immunological consequences. The value of the new work lies precisely in identifying a distal, element-level control point that may be more selective than targeting the transcription factor itself, though translating that selectivity into clinical tools remains a distant goal.

The study also speaks to a broader shift in how human immunology is conducted. For years, much of what immunologists knew about transcriptional regulation in T cells came from murine models, and the conservation of distal regulatory elements between species is notoriously imperfect. Enhancers can be rapidly evolved regions of the genome, and a regulatory element discovered in mouse T cells may not exist, or may not function equivalently, in human T cells. By focusing on human regulatory T cells and mapping the chromatin landscape that governs their fate under inflammatory pressure, Tang and colleagues contribute to a growing body of work that grounds immune regulatory principles directly in human genomic architecture. Such human-first studies are increasingly recognized as essential for ensuring that fundamental discoveries translate reliably into medicine.

The image that emerges from the study is one of the genome as an active participant in immune cell decision-making, not merely a static blueprint. A regulatory element located distally from IRF4, engaging with the three-dimensional architecture of chromatin, integrates inflammatory signals and transmits them to the transcriptional core of the regulatory T cell program. Remove that element, and the inflammatory signal finds no route into the fate machinery; the cell remains a suppressor. The finding reframes Treg plasticity not as a stochastic failure of identity but as a genomically encoded, mechanistically defined process with a specific address in the human genome. As immunologists continue to dissect the enhancer landscapes of immune cells, studies of this kind point toward a future in which the stability of therapeutic or endogenous regulatory T cells can be understood, predicted, and perhaps deliberately controlled at the level of the DNA elements that choreograph their fates.

Subject of Research: A distal IRF4 chromatin regulatory element controlling inflammatory reprogramming of human regulatory T cells

Article Title: Deletion of a distal IRF4 element prevents inflammation-induced reprogramming of human regulatory T cell fate

Article References: Ho, P., Vu, A., Leung, J., Rosenthal, W., Ntranos, V., Bluestone, J. A., & Tang, Q. (2026). Deletion of a distal IRF4 element prevents inflammation-induced reprogramming of human regulatory T cell fate. Nature Immunology, 27(10), 2143-2155. https://doi.org/10.1038/s41590-026-02655-8

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02655-8

Keywords: regulatory T cells, IRF4, chromatin regulation, distal enhancer, Treg plasticity, inflammation, FOXP3, transcription factors, autoimmunity, cancer immunology, genome editing, human immunology